Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial.

Sibeko S, Baxter C, Yende N, Karim QA, Karim SS.

Obstet Gynecol. 2011 Oct;118(4):895-904. doi: 10.1097/AOG.0b013e31822be512.

2.

Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.

Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH, Roux S, Mathebula M, Naicker N, Ducar C, Carter DK, Puren A, Eaton N, McElrath MJ, Robertson M, Corey L, Kublin JG; HVTN 503/Phambili study team.

Lancet Infect Dis. 2011 Jul;11(7):507-15. doi: 10.1016/S1473-3099(11)70098-6. Epub 2011 May 11. Erratum in: Lancet Infect Dis. 2011 Jul;11(7):495.

3.

Predictors of pregnancy in microbicide trials.

Halpern V, Lie CC, Feldblum P, Van Damme L; Microbicide Research Group.

Contraception. 2011 May;83(5):436-40. doi: 10.1016/j.contraception.2010.08.018. Epub 2010 Oct 8.

PMID:
21477686
4.

Time-to-pregnancy and pregnancy outcomes in a South African population.

Bello B, Kielkowski D, Heederik D, Wilson K.

BMC Public Health. 2010 Sep 21;10:565. doi: 10.1186/1471-2458-10-565.

5.

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D; CAPRISA 004 Trial Group.

Science. 2010 Sep 3;329(5996):1168-74. doi: 10.1126/science.1193748. Epub 2010 Jul 19. Erratum in: Science. 2011 Jul 29;333(6042):524.

6.

Are women who work in bars, guesthouses and similar facilities a suitable study population for vaginal microbicide trials in Africa?

Vallely A, Hambleton IR, Kasindi S, Knight L, Francis SC, Chirwa T, Everett D, Shagi C, Cook C, Barberousse C, Watson-Jones D, Changalucha J, Ross D, Hayes RJ; Microbicides Development Programme.

PLoS One. 2010 May 14;5(5):e10661. doi: 10.1371/journal.pone.0010661.

7.

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH; MOPH-TAVEG Investigators.

N Engl J Med. 2009 Dec 3;361(23):2209-20. doi: 10.1056/NEJMoa0908492. Epub 2009 Oct 20.

8.

Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women.

Reid SE, Dai JY, Wang J, Sichalwe BN, Akpomiemie G, Cowan FM, Delany-Moretlwe S, Baeten JM, Hughes JP, Wald A, Celum C.

J Acquir Immune Defic Syndr. 2010 Apr;53(5):606-13. doi: 10.1097/QAI.0b013e3181bc4869.

9.

Contraceptive use in women enrolled into preventive HIV vaccine trials: experience from a phase I/II trial in East Africa.

Kibuuka H, Guwatudde D, Kimutai R, Maganga L, Maboko L, Watyema C, Sawe F, Shaffer D, Matsiko D, Millard M, Michael N, Wabwire-Mangen F, Robb M.

PLoS One. 2009;4(4):e5164. doi: 10.1371/journal.pone.0005164. Epub 2009 Apr 10.

10.

Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial.

Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, Govender S, De Kock A, Cassim N, Palanee T, Dozier G, Maguire R, Lahteenmaki P.

Lancet. 2008 Dec 6;372(9654):1977-87. doi: 10.1016/S0140-6736(08)61842-5.

PMID:
19059048
11.

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN; Step Study Protocol Team.

Lancet. 2008 Nov 29;372(9653):1881-93. doi: 10.1016/S0140-6736(08)61591-3. Epub 2008 Nov 13.

12.

SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana.

Peterson L, Nanda K, Opoku BK, Ampofo WK, Owusu-Amoako M, Boakye AY, Rountree W, Troxler A, Dominik R, Roddy R, Dorflinger L.

PLoS One. 2007 Dec 19;2(12):e1312.

13.

The value of site preparedness studies for future implementation of phase 2/IIb/III HIV prevention trials: experience from the HPTN 055 study.

Ramjee G, Kapiga S, Weiss S, Peterson L, Leburg C, Kelly C, Masse B; HPTN 055 Study Team.

J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):93-100.

PMID:
17984760
14.

Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial.

Padian NS, van der Straten A, Ramjee G, Chipato T, de Bruyn G, Blanchard K, Shiboski S, Montgomery ET, Fancher H, Cheng H, Rosenblum M, van der Laan M, Jewell N, McIntyre J; MIRA Team.

Lancet. 2007 Jul 21;370(9583):251-61.

15.

Pregnancy in effectiveness trials of HIV prevention agents.

Raymond EG, Taylor D, Cates W Jr, Tolley EE, Borasky D, Cancel A, Masse B, Bukusi EA, Johnson BR.

Sex Transm Dis. 2007 Dec;34(12):1035-9. No abstract available.

PMID:
17621249
16.

Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study.

Cao H, Kaleebu P, Hom D, Flores J, Agrawal D, Jones N, Serwanga J, Okello M, Walker C, Sheppard H, El-Habib R, Klein M, Mbidde E, Mugyenyi P, Walker B, Ellner J, Mugerwa R; HIV Network for Prevention Trials.

J Infect Dis. 2003 Mar 15;187(6):887-95. Epub 2003 Mar 6.

Items per page

Supplemental Content

Write to the Help Desk